- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2014-10-03 16:09:13
- Reporting Period:
- Filing Date:
- Accepted Time:
- 2014-10-03 16:09:13
- SEC Url:
- Form 4 Filing
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|1488613||Foundation Medicine Inc.||FMI||Services-Medical Laboratories (8071)||271316416|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1457809||Kevin Krenitsky||150 Second Street |
C/o Foundation Medicine, Inc.
Cambridge MA 02141
|Chief Commercial Officer & Svp||No||Yes||No||No|
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
- Acquired pursuant to vesting and release of shares on September 30, 2014 pursuant to a Restricted Stock Unit award granted on April 9, 2014.
- The reporting person previously reported all restricted stock units granted to the reporting person on April 9, 2014 in Table I of the Form 4/A filed on May 27, 2014. As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect this vesting event.
- Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person.
- The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.70 to $18.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.